BAJAJHCARE - Bajaj Healthcare
📢 Recent Corporate Announcements
Bajaj Healthcare Limited has successfully passed seven special resolutions via postal ballot as of February 19, 2026. Key approvals include the re-appointment of Mr. Sajankumar Rameshwarlal Bajaj as Chairman & Managing Director and Mr. Anil Champalal Jain as Managing Director. The company also appointed three new Non-Executive Independent Directors to its board. While all resolutions passed with the requisite majority, Resolution 7 faced significant dissent from public institutional voters.
- Re-appointment of Sajankumar Rameshwarlal Bajaj as CMD passed with 99.99% of total votes in favor.
- Three new Independent Directors (Mr. Vaghela, Mrs. Amin, and Mr. Bhavsar) were officially inducted into the board.
- Total of 19.3 million votes were polled, representing 61.13% of the total outstanding shares.
- Resolution 7 regarding the re-appointment of Mr. Pakshal Anil Jain saw 99.99% of voting public institutions (599,840 votes) voting against.
- All 7 resolutions were special resolutions and passed with the required majority as per SEBI regulations.
Bajaj Healthcare Limited has updated its list of Key Managerial Personnel (KMP) authorized to determine event materiality and handle stock exchange disclosures. Under Regulation 30(5) of SEBI (LODR) Regulations, 2015, Managing Director Mr. Anil Champalal Jain and CFO Mr. Rohan Parekh are authorized to determine the materiality of information. Company Secretary Ms. Monica Tanwar is designated to execute the actual disclosures to the exchanges. This is a standard administrative update to ensure compliance with corporate governance norms.
- Authorized MD Anil Champalal Jain and CFO Rohan Parekh to determine event materiality
- Designated CS Monica Tanwar for making requisite disclosures to BSE and NSE
- Update issued in compliance with Regulation 30(5) of SEBI (LODR) Regulations, 2015
- Provided centralized contact details via investors@bajajhealth.com and +91-22-66177400
Bajaj Healthcare reported a strong 31.3% YoY growth in revenue from operations, reaching ₹161.22 crore for Q3 FY26. Net profit for the quarter surged by 33.7% YoY to ₹15.67 crore, aided by improved performance in continuing operations and significantly reduced losses from discontinued units. The company also announced the re-appointment of its top leadership, including the Chairman and Managing Directors, for another three-year term starting April 2026. Nine-month performance remains robust with total profit increasing to ₹38.62 crore compared to ₹28.32 crore in the previous year.
- Revenue from operations grew 31.3% YoY to ₹16,122.27 lakhs in Q3 FY26.
- Net profit for the period increased 33.7% YoY to ₹1,567.38 lakhs.
- 9M FY26 total income reached ₹46,215.16 lakhs compared to ₹39,396.27 lakhs in 9M FY25.
- Losses from discontinued operations narrowed significantly to ₹42.71 lakhs from ₹324.44 lakhs YoY.
- Board approved the re-appointment of the core promoter management team for a 3-year term starting April 2026.
Bajaj Healthcare has issued a postal ballot notice to seek shareholder approval for the appointment of three Independent Directors and the re-appointment of four key executive leaders. The executive re-appointments, including the Chairman & Managing Director and Managing Director, are for three-year terms starting April 1, 2026. The three new Independent Directors are proposed for five-year terms to enhance board oversight and governance. Shareholders can cast their votes electronically from January 20 to February 19, 2026.
- Re-appointment of Sajankumar Rameshwarlal Bajaj as CMD for a 3-year term starting April 1, 2026
- Proposed appointment of 3 new Independent Directors for 5-year terms to strengthen board governance
- Re-appointment of Anil Champalal Jain as MD and two other Whole-Time Directors for 3-year terms
- E-voting period scheduled from January 20, 2026, to February 19, 2026
- Cut-off date for eligibility to vote is January 16, 2026
Bajaj Healthcare reported a strong Q3 FY26 with revenue growing 31.3% YoY to Rs. 1,612.2 Mn, primarily driven by a massive 109.8% surge in API exports. EBITDA margins improved slightly to 19.8%, leading to a 33.7% YoY increase in net profit to Rs. 156.7 Mn. The company achieved a significant regulatory milestone as the first Indian firm to receive CDSCO approval for Phase III trials of Suvorexant. For the nine-month period, PAT grew by 36.4%, reflecting sustained momentum in regulated markets and specialty drug development.
- Revenue from operations grew 31.3% YoY to Rs. 1,612.2 Mn in Q3 FY26.
- API Export revenue more than doubled, growing 109.8% YoY to Rs. 486.8 Mn.
- EBITDA increased by 34.6% YoY to Rs. 323.3 Mn with margins expanding to 19.8%.
- Profit for the period (PAT) rose 33.7% YoY to Rs. 156.7 Mn.
- Filed 9 DMFs during the quarter, bringing the cumulative total to 69 filings.
Bajaj Healthcare's Board has approved the re-appointment of its core leadership team, including Chairman & MD Sajankumar Bajaj and MD Anil Jain, for three-year terms. These appointments, effective from April 1, 2026, ensure management continuity for the company's API and formulation divisions. Additionally, two Whole-Time Directors, Ms. Namrata Bajaj and Mr. Pakshal Jain, were re-appointed for similar tenures. The board also approved the un-audited financial results for the quarter and nine months ended December 31, 2025, during the same session.
- Re-appointment of Mr. Sajankumar Rameshwarlal Bajaj as Chairman & MD for 3 years effective April 1, 2026.
- Re-appointment of Mr. Anil Champalal Jain as Managing Director for a 3-year term ending March 31, 2029.
- Two Whole-Time Directors re-appointed for 3-year tenures to oversee Sales, Marketing, and API development.
- Board approved un-audited financial results for the quarter and nine months ended December 31, 2025.
- All leadership extensions are subject to shareholder approval via a forthcoming postal ballot.
Bajaj Healthcare has approved its un-audited financial results for the quarter and nine months ended December 31, 2025. The board has also approved the re-appointment of four key executive directors, including the Chairman and Managing Director, for new three-year terms starting in 2026. These leaders, including Mr. Sajankumar Bajaj and Mr. Anil Jain, have over 30 years of experience with the company. The re-appointments are subject to shareholder approval via a postal ballot.
- Approved un-audited financial results for the quarter and nine months ended December 31, 2025.
- Re-appointed Sajankumar Rameshwarlal Bajaj as Chairman & MD for 3 years effective April 1, 2026.
- Re-appointed Anil Champalal Jain as Managing Director for a 3-year term starting April 1, 2026.
- Extended the terms of Whole-Time Directors Namrata Bajaj and Pakshal Jain for 3 years each.
- The board meeting was conducted on January 16, 2026, between 4:15 PM and 5:00 PM.
Bajaj Healthcare Limited has appointed Mr. Umeshkumar Laxmidas Bhavsar as an Additional Director in the Non-Executive Independent category effective January 13, 2026. Mr. Bhavsar is a Chartered Accountant with over 35 years of experience in financial leadership and strategic planning across sectors like real estate and manufacturing. His appointment is for a first term of 5 consecutive years, ending January 12, 2031, subject to shareholder approval. He previously served for 15 years at Ajmera Realty & Infra India Limited, bringing significant domain expertise to the board.
- Appointment of Mr. Umeshkumar Laxmidas Bhavsar as Non-Executive Independent Director effective Jan 13, 2026.
- The appointee brings over 35 years of professional experience as a Chartered Accountant.
- The tenure is fixed for a period of 5 years, concluding on January 12, 2031.
- Mr. Bhavsar previously spent 15 years at Ajmera Realty & Infra India Limited in financial leadership roles.
Bajaj Healthcare Limited has filed the compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. The certificate, issued by MUFG Intime India Private Limited, confirms that all securities received for dematerialization were processed and listed on the stock exchanges. It also verifies that physical certificates were mutilated and cancelled after due verification within the prescribed timelines. This is a standard administrative filing ensuring the integrity of the company's shareholding records.
- Compliance certificate submitted for the quarter ended December 31, 2025.
- Issued by Registrar and Transfer Agent (RTA) MUFG Intime India Private Limited.
- Confirms dematerialization requests were accepted/rejected and processed within timelines.
- Verification that physical certificates were mutilated and cancelled as per SEBI norms.
Bajaj Healthcare has appointed Mrs. Purnima Dhanraj Amin as an Additional Non-Executive Independent Director for a five-year term starting January 05, 2026. Mrs. Amin brings over 32 years of academic and research experience from the Institute of Chemical Technology (ICT), Mumbai, specializing in pharmaceutics. Her expertise in Hot Melt Extrusion (HME) technology and drug delivery systems is expected to provide significant technical oversight to the board. The appointment is subject to shareholder approval and aligns with SEBI's independence regulations.
- Appointment of Mrs. Purnima Dhanraj Amin as Independent Director for a 5-year term effective January 05, 2026.
- The appointee holds a Ph.D. in Pharmaceutics and has over 32 years of research and academic experience at ICT Mumbai.
- Specialization in Hot Melt Extrusion (HME) technology for innovative drug delivery systems including oral and parenteral formulations.
- The appointment is valid until January 04, 2031, subject to upcoming shareholder approval.
Bajaj Healthcare Limited has received formal approval from the CDSCO to conduct Phase III Clinical Trials and Bioequivalence Studies for Suvorexant Tablets. This approval, granted on December 31, 2025, follows an earlier recommendation by the Subject Expert Committee for Neurology & Psychiatry. Suvorexant is a medication used to treat insomnia, representing an expansion into specialized therapeutic areas. Successful completion of these trials is a prerequisite for commercial launch in India.
- CDSCO approval granted on Dec 31, 2025, for Suvorexant Clinical Trials and Bioequivalence Study.
- Follows previous Subject Expert Committee (SEC) recommendation from October 04, 2025.
- The drug targets the Neurology & Psychiatry segment, specifically for insomnia treatment.
- Enables the company to proceed with critical Phase III trials required for market entry.
Bajaj Healthcare Limited has announced the closure of its trading window for all designated persons and their relatives starting January 1, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of financial results. The closure pertains to the un-audited financial results for the quarter and nine months ending December 31, 2025. The window will remain closed until 48 hours after the results are officially declared to the exchanges.
- Trading window closure effective from Thursday, January 1, 2026.
- Closure is related to the un-audited financial results for the quarter and nine months ended December 31, 2025.
- Window to reopen 48 hours after the financial results are declared.
- Applies to all insiders, designated persons, and their immediate relatives as per SEBI regulations.
Bajaj Healthcare (BHL) is pivoting towards high-margin segments, including a new 250 kg/annum peptide plant scheduled for March 2026 targeting the GLP-1 (Semaglutide) market. The company has solidified its position as a key government partner in alkaloid extraction with capacities of 250 MT for opium gum and 2,500 MT for poppy straw. BHL is also expanding its CDMO footprint through a 30-API agreement with UK/EU clients and a dedicated oncology API plant expected by 2027. With a low debt-to-equity ratio of 0.45 and 20 manufacturing facilities, the company is well-positioned for its next phase of growth.
- Commissioned India's first poppy straw plant with 2,500 MTPA capacity under a Government of India contract.
- Developing a 250 kg/annum peptide synthesis plant targeting anti-diabetic and weight-loss molecules by March 2026.
- Entered a definitive CDMO agreement for the supply of 30 new APIs to customers in the UK and EU.
- Constructing a dedicated Oncology API plant expected to be ready by 2027 to complement its existing formulation unit.
- Maintains a strong balance sheet with a Debt/Equity ratio of 0.45 and zero USFDA 483 observations at its Vadodara facility.
Bajaj Healthcare Limited will be interacting with analysts and institutional investors in meetings scheduled for December 8th and 9th, 2025, in Mumbai. These meetings are in compliance with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The meetings will be a mix of one-on-one and group interactions. The company has stated that no unpublished price-sensitive information will be shared during these interactions. The schedule is subject to change based on exigencies.
- Analyst/Institutional Investor Meetings scheduled for 08th December 2025 - 09th December 2025
- Meetings are pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
- Meetings to be held in Mumbai
Financial Performance
Revenue Growth by Segment
Not disclosed in available documents. However, the company achieved a significant financial turnaround with a profit of INR 39.50 Cr in FY25 compared to a loss of INR 83.80 Cr in FY24.
Profitability Margins
Net profit for FY25 stood at INR 39.50 Cr, representing a recovery from a loss of INR 83.80 Cr in FY24. Profit for the period ending September 2025 was INR 22.94 Cr. Discontinued operations significantly impacted past margins, with a loss of INR 69.46 Cr in FY24 narrowing to a loss of INR 3.43 Cr in FY25.
EBITDA Margin
Not disclosed in available documents. However, Profit after Taxes & Exceptional items improved from a loss of INR 14.34 Cr in FY24 to a profit of INR 42.93 Cr in FY25.
Capital Expenditure
Net Fixed Assets & CWIP stood at INR 241.90 Cr as of March 31, 2025, compared to INR 259.37 Cr in FY24. The company raised INR 204.97 Cr through a preferential issue of equity shares and convertible warrants in September 2024 to fund business requirements.
Credit Rating & Borrowing
The company holds an IND A2+ rating for non-fund-based working capital limits. Total borrowings were reduced by 34.55%, falling from INR 362.60 Cr in FY24 to INR 237.32 Cr in FY25. Borrowings further decreased to INR 227.87 Cr by September 2025.
Operational Drivers
Raw Materials
Not disclosed in available documents. The company operates in the pharmaceutical sector, implying usage of Active Pharmaceutical Ingredients (APIs) and chemical intermediates.
Capacity Expansion
Not disclosed in available documents. However, the appointment of Shreekumar Nair as COO (with 40+ years of experience in process optimization at Alembic and Glenmark) suggests a focus on operational management and supply chain transformation.
Manufacturing Efficiency
The company focuses on process optimization and operational management, led by the Senior Management Team including the newly appointed COO, Shreekumar Nair.
Strategic Growth
Growth Strategy
Growth is targeted through a combination of capital infusion (INR 204.97 Cr raised in FY25), leadership strengthening (appointment of a new COO and CFO with Glenmark/Alembic backgrounds), and a focus on core operations by reducing losses from discontinued operations (which fell from INR 69.46 Cr to INR 3.43 Cr YoY).
Products & Services
Pharmaceutical products including Active Pharmaceutical Ingredients (APIs) and formulations.
Brand Portfolio
Bajaj Healthcare.
Market Expansion
The company is actively engaging with institutional investors and analysts (meetings scheduled for December 8-9, 2025) to support its market expansion and visibility.
External Factors
Industry Trends
The company is positioning itself within the pharmaceutical industry by hiring veterans from major players like Glenmark and Alembic, indicating a shift toward higher operational standards and potentially more complex product portfolios.
Competitive Landscape
Competes in the pharmaceutical API and formulation space; specific competitor names were not listed in the documents.
Competitive Moat
The company's moat is built on its integrated manufacturing capabilities and a leadership team with deep industry expertise (CFO and COO have 14+ and 40+ years of experience respectively).
Geopolitical Risks
The Risk Management Committee monitors external risks, though specific geopolitical exposures are not detailed.
Regulatory & Governance
Industry Regulations
Compliant with SEBI (LODR) Regulations 2015 and the Companies Act 2013. The company maintains a Code of Conduct for Insider Trading and a Vigil Mechanism.
Environmental Compliance
The Risk Management Committee is responsible for sustainability and ESG-related risks.
Taxation Policy Impact
The company reported a tax credit/adjustment of INR 0.54 Cr for FY23 and a tax expense of INR 17.72 Cr for FY24.
Legal Contingencies
No instances of non-compliance or penalties were imposed by Stock Exchanges, SEBI, or any statutory authority regarding capital markets in the last three years.
Risk Analysis
Key Uncertainties
The primary uncertainty involves the final resolution of discontinued operations, which had a negative impact of INR 3.43 Cr in FY25. Cyber security and information risks are also monitored by the Risk Management Committee.
Technology Obsolescence Risk
The company addresses technology risks through its Risk Management Committee and the appointment of a Chief Technical Officer (Amit Rajan).
Credit & Counterparty Risk
The company maintains internal controls for financial reporting to manage credit and financial risks; no significant fraud or internal control failures were reported in FY25.